Diseases & Longevity · File 20

Metabolic syndrome. The named cardiometabolic cluster — and fully modifiable.

Metabolic syndrome is the clinically named cardiometabolic cluster. Harmonized criteria (Alberti 2009 Circulation, IDF + AHA/NHLBI + WHO + IAS + IASO) require 3 of 5: increased waist circumference, high triglycerides, low HDL, hypertension, high fasting glucose. It is an independent predictor of T2D, cardiovascular events, stroke, and MASLD. Longevity medicine treats it as a central target for its population weight and sustained modifiability.

Why naming the cluster changes the clinical conversation

Naming the cardiometabolic cluster as a clinical entity — metabolic syndrome — changes the patient's and clinician's view. Instead of treating HTN, dyslipidemia, prediabetes, and obesity separately (with 4 different consultations), metabolic syndrome recognizes them as manifestations of a shared underlying mechanism: insulin resistance + inflammaging + endothelial dysfunction + altered adipokines.

Clinical recognition changes intervention: an integrated intervention (structured lifestyle + pharmacological when indicated + comorbidity management) has multiplicative effect on individual components. Longevity medicine already operated on this logic before it was formalized — metabolic syndrome is simply the clinical name for what the cardiometabolic cluster already describes.

Treating HTN + T2D + dyslipidemia + obesity separately is losing the conversation. They are the same cluster — and the same patient.
Global adult prevalence

The global weight, in numbers

Quantitative metabolic syndrome data come from NHANES (US), ENSANUT (Mexico), European cohorts, and global meta-analyses — confirm sustained growth.

  • Global prevalence

    ~25% adultos

    Approximately 25% of adults globally meet metabolic syndrome criteria — exceeds 30% in US (NHANES). In Latin America prevalence is high — Mexico, Colombia, and Brazil report growing figures.
    — Saklayen, Curr Hypertens Rep 2018

  • T2D risk

    ×5

    Metabolic syndrome patients have approximately 5× higher risk of developing T2D at 5-10 years — underlying insulin resistance is the central mechanism.
    — Ford et al., Diabetes Care 2008

  • Cardiovascular risk

    ×2 eventos CV

    Metabolic syndrome doubles the risk of major cardiovascular events (MI, stroke, CV death) in longitudinal cohorts — independent of T2D risk.
    — Mottillo et al., JACC 2010

  • Expected growth

    Sostenido en LATAM

    Due to urbanization, ultra-processed diet, and sedentarism, prevalence grows sustainably — especially in young adults in Latin America and Asia. Early detection is public health priority.
    — NCD-RisC, Lancet 2017

Chap. 03 · Systemic comorbidities

Impact on amplified cluster and systemic comorbidity

Metabolic syndrome is not only cardiometabolic — its substrate (inflammaging + insulin resistance) amplifies multiple longevity biological axes.

  • Coexistent MASLD

    ~70% de pacientes

    Up to 70% of metabolic syndrome patients have coexistent MASLD. New nomenclature (MASLD 2023) formalizes this link. FIB-4 screening is frequent indication.
    — AASLD 2023; EASL 2024

  • Cancer risk

    Inflamación + IGF-1

    Metabolic syndrome increases risk of obesity-associated cancers (colorectal, postmenopausal breast, endometrium, liver, pancreas) through shared mechanism inflammaging + insulin/IGF-1.
    — Lauby-Secretan, NEJM 2016

  • Cognitive decline and dementia

    Cluster Lancet 2024

    Three of the 14 Lancet Commission 2024 factors are direct components of metabolic syndrome (HTN, T2D, obesity). Their integrated management is dementia prevention.
    — Livingston et al., Lancet 2024

  • Sleep apnea (OSA)

    Cluster amplificador

    OSA and metabolic syndrome mutually amplify — they share central obesity, inflammaging, and dysautonomia. Polysomnography is indicated in cases with suggestive symptoms.
    — Lévy et al., Nat Rev Dis Primers 2015

What we don't offer — and what we do

Wellness Care does not replace endocrinology, cardiology, or hepatology in individualized pharmacological management of metabolic syndrome components. Choice of antihypertensive, lipid-lowering, oral antidiabetic, SGLT2i, GLP-1, and others is the specialist's competence. What we do is what the conventional system rarely integrates: systemic cluster evaluation and inter-specialty coordination.

We evaluate patients meeting 2-3 criteria (emerging cluster) or with established metabolic syndrome under medical management but wanting to optimize the longevity view. Evaluation integrates: body composition, advanced lipid profile (ApoB, Lp(a)), HbA1c + insulin + HOMA, ABPM when applicable, FIB-4 (MASLD), inflammaging (hsCRP), polysomnography when OSA is suspected, and the 14 modifiable factors. Coordination with all relevant specialties.

Metabolic syndrome is the named cluster. Integrated intervention is not optional — it is where cardiometabolic longevity is really decided.
How we measure it

How metabolic syndrome is evaluated
at Wellness Care

The 5 criteria expanded with advanced biomarkers + systemic cluster + inter-specialist coordination. That changes real trajectory.

Advanced biomarkers

21 specialized panels across 8 clinical categories — biological age, inflammaging, metabolic profile, functional hormonal, microbiota. The quantitative layer.

Explore →

Functional medicine

Shared root causes — mitochondrial dysfunction, inflammaging, neuroendocrine dysregulation — before organ pathology.

Explore →

Bioregulatory medicine

Autonomic regulation, HRV, stress response. The functional trajectory that precedes clinical diagnosis.

Explore →

The Longevity Program

How this assessment integrates into the full program — from initial valuation to individualized protocol design under medical judgment.

Explore →
Featured evidence

Key evidence supporting this approach

Four publications structuring the metabolic syndrome conversation — harmonized criteria, CV and T2D risk, cancer association.

«El síndrome metabólico se define por 3 de 5 criterios: perímetro abdominal, triglicéridos, HDL, presión arterial y glucosa en ayuno — la harmonización 2009 unificó las definiciones previas.»
Circulation · 2009
Alberti et al., Circulation 2009
Criterios harmonizados
«El síndrome metabólico duplica el riesgo de eventos cardiovasculares mayores y multiplica por 5 el riesgo de DM2 a 5-10 años.»
JACC · 2010
Mottillo et al., JACC 2010
Meta-análisis riesgo CV
«La prevalencia del síndrome metabólico crece sostenidamente — afecta aproximadamente al 25% de los adultos globalmente y supera el 30% en EE.UU.»
Curr Hypertens Rep · 2018
Saklayen, Curr Hypertens Rep 2018
Epidemiología global

Frequently asked questions about metabolic syndrome

The most recurrent questions about metabolic syndrome, its criteria, integrated intervention, and why longevity medicine operates on the cluster, not on individual components.

01

What are the 5 exact metabolic syndrome criteria?

Per Alberti 2009 (Circulation) harmonization: 3 of 5

1. Increased waist circumference
    · >102 cm men
    · >88 cm women (adjusted by ethnicity)

2. Triglycerides ≥150 mg/dL or specific treatment

3. Low HDL
    · <40 men
    · <50 women mg/dL

4. Hypertension ≥130/85 mmHg or treatment

5. Fasting glucose ≥100 mg/dL or established T2D

Meeting 3 criteria defines the syndrome.

02

Is metabolic syndrome the same as prediabetes?

No.

Prediabetes is one of the metabolic syndrome criteria:

· Fasting glucose 100-125 mg/dL
· HbA1c 5.7-6.4%

Metabolic syndrome is broader — also includes dyslipidemia, HTN, and central obesity.

· A patient can have metabolic syndrome without prediabetes if meeting 3 of the other 4 criteria
· A patient with isolated prediabetes doesn't have metabolic syndrome — but still has significant risk

03

What interventions really reverse metabolic syndrome?

Integrated interventions with demonstrated effect:

· Sustained 5-10% body weight loss
· Mediterranean or DASH diet
· Strength + cardio training
· Sleep and stress management
· OSA treatment if present

In selected patients, GLP-1 (semaglutide, tirzepatide) significantly reduce cluster components.

Combined intervention has multiplicative effect — treating isolated components is suboptimal.

04

Does metabolic syndrome increase cancer risk?

Yes.

Multiple meta-analyses show metabolic syndrome increases risk of obesity-associated cancers:

· Colorectal
· Postmenopausal breast
· Endometrium
· Kidney
· Liver
· Esophagus
· Pancreas

Shared mechanisms:

· Chronic inflammation
· Hyperinsulinemia with elevated IGF-1
· Altered adipokines

That expands the longevity conversation: cluster management is also oncologic prevention.

05

When should I consult?

A structured assessment is worthwhile if:

· You meet 2 or more criteria of metabolic syndrome
· You have prediabetes
· Your waist circumference is increased even though BMI is normal
· Family history of T2D / early MI
· Already established metabolic syndrome under medical management but want to optimize the longevity view

The assessment integrates the cluster — does not replace endocrinology, cardiology, or hepatology, complements them.

The cluster with a clinical name

Metabolic syndrome is the cardiometabolic cluster with a clinical name. Treating its components separately is losing the conversation.

Evaluate the 5 criteria expanded with advanced biomarkers, integrate all cluster comorbidities, and coordinate between specialties — that's what's missing in the fragmented model.

Do you already meet 3 of 5 cluster criteria?

Book a comprehensive cardiometabolic cluster assessment

We evaluate the 5 cluster criteria (waist, TG, HDL, BP, glucose) expanded with advanced biomarkers — ApoB, Lp(a), HbA1c, insulin, HOMA index, hsCRP, FIB-4, body composition. The assessment does not replace endocrinology or cardiology — it complements them with the longevity view.

Book comprehensive metabolic assessment